Methylation of the tumor suppressor gene RASSF1A in human tumors
- PMID: 15948711
- DOI: 10.1007/s10541-005-0151-y
Methylation of the tumor suppressor gene RASSF1A in human tumors
Abstract
Loss of heterozygosity of a segment at 3p21.3 is frequently observed in lung cancer and several other carcinomas. We have identified the Ras-association domain family 1A gene (RASSF1A), which is localized at 3p21.3 in a minimum deletion sequence. De novo methylation of the RASSF1A promoter is one of the most frequent epigenetic inactivation events detected in human cancer and leads to silencing of RASSF1A expression. Hypermethylation of RASSF1A was frequently found in most major types of human tumors including lung, breast, prostate, pancreas, kidney, liver, cervical, thyroid and many other cancers. The detection of RASSF1A methylation in body fluids such as serum, urine, and sputum promises to be a useful marker for early cancer detection. The functional analysis of RASSF1A reveals a potential involvement of this protein in apoptotic signaling, microtubule stabilization, and cell cycle progression.
Similar articles
-
The tumor suppressor RASSF1A in human carcinogenesis: an update.Histol Histopathol. 2005 Apr;20(2):645-63. doi: 10.14670/HH-20.645. Histol Histopathol. 2005. PMID: 15736067 Review.
-
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.Cancer Res. 2001 Oct 1;61(19):7277-81. Cancer Res. 2001. PMID: 11585766
-
Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.Clin Cancer Res. 2002 Jul;8(7):2362-8. Clin Cancer Res. 2002. PMID: 12114441
-
Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.Eur J Cancer. 2002 Aug;38(12):1585-92. doi: 10.1016/s0959-8049(01)00422-1. Eur J Cancer. 2002. PMID: 12142046
-
Methylation of the RASSF1A gene in human cancers.Biol Chem. 2002 Jun;383(6):907-14. doi: 10.1515/BC.2002.097. Biol Chem. 2002. PMID: 12222680 Review.
Cited by
-
The role of aberrant DNA methylation in cancer initiation and clinical impacts.Ther Adv Med Oncol. 2024 Jan 28;16:17588359231220511. doi: 10.1177/17588359231220511. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38293277 Free PMC article.
-
DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach.Br J Cancer. 2015 Mar 17;112(6):1105-13. doi: 10.1038/bjc.2014.636. Br J Cancer. 2015. PMID: 25719833 Free PMC article.
-
Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.World J Gastroenterol. 2008 May 21;14(19):3074-80. doi: 10.3748/wjg.14.3074. World J Gastroenterol. 2008. PMID: 18494062 Free PMC article.
-
Epigenetic alterations in RASSF1A in human aberrant crypt foci.Carcinogenesis. 2006 Jul;27(7):1316-22. doi: 10.1093/carcin/bgi373. Epub 2006 Mar 2. Carcinogenesis. 2006. PMID: 16513682 Free PMC article.
-
Epigenetic activation of LY6K predicts the presence of metastasis and poor prognosis in breast carcinoma.Oncotarget. 2016 Aug 23;7(34):55677-55689. doi: 10.18632/oncotarget.10972. Oncotarget. 2016. PMID: 27494879 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources